콘텐츠로 건너뛰기
Merck

920436

NanoFabTx PEG-PLA drug formulation screening kit

for synthesis of PEGylated nanoparticles

동의어(들):

Microfluidics, NanoFabTx reagent kit, Nanoformulation, Nanoparticle kit, PEG-PLA

조직 및 계약 가격을 보려면 로그인를 클릭합니다.

크기 선택

보기 변경

제품정보 (DICE 배송 시 비용 별도)

NACRES:
NA.23
UNSPSC Code:
12161503
Storage temp.:
2-8°C
기술 서비스
도움이 필요하신가요? 저희 숙련된 과학자 팀이 도와드리겠습니다.
도움 문의


Quality Level

description

Kit components :
PEGPLA-L-M (919942-500mg)
PEGPLA-H-M (919934-500mg)
Stabilizer-Nano (907766-5g), PEG-PLA drug formulation screening kit, for synthesis of PEGylated PLA nanoparticles

application(s)

advanced drug delivery

storage temp.

2-8°C

General description

NanoFabTx PEG-PLA drug formulation screening kit is a nanoformulation kit containing rationally selected PEGylated PLA polymers that have been used widely for controlled drug release of many different types of therapeutic molecules. The kit contains protocols for two different particle synthesis methods:
  • A Nanoprecipitation protocol to prepare drug-encapsulated nanoparticles in standard laboratory glassware.
  • A Microfluidics protocol using commercial platforms or syringe pumps.
The microfluidics protocol uses NanoFabTx device kits (911593), which provide all the microfluidics chips, fittings, and tubing required to get started with microfluidics-based synthesis (compatible microfluidics system or syringe pump required).

Application

NanoFabTx PEG-PLA drug formulation screening kit enables users to encapsulate a wide variety of therapeutic drug molecules in specifically sized, biodegradable, PEGylated PLA nanoparticles. By simplifying the chemistry and providing an easy-to-use toolkit with step-by-step instructions, our NanoFabTx nanoformulation screening kit helps researchers achieve reproducible synthesis of drug encapsulating nanoparticles with narrow size dispersity, eliminating the need for lengthy trial-and-error optimization. Suitable for biomedical research applications such as oncology, immuno-oncology, gene delivery, and vaccine delivery, PEG-PLA nanoparticles, made using the NanoFabTx PEG-PLA drug formulation screening kit, are designed for maximizing the encapsulation of hydrophobic drugs to minimize the time and expensive wasted reagents of synthetic optimization.

Features and Benefits

  • Includes tested protocols with step-by-step instructions for nanoprecipitation or microfluidics-based syntheses
  • Requires minimal laboratory setup
  • Optimized to achieve monodisperse, homogenously shaped, biodegradable, PEGylated PLA nanoparticles in any size between 60 and 100 nm
  • Formulated to maximize the encapsulation of hydrophobic drugs
  • Includes two different PEGylated PLAs

Legal Information

NANOFABTX is a trademark of Sigma-Aldrich Co. LLC


저장 등급

10 - Combustible liquids



가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 문서 section.

도움이 필요하시면 연락하세요. 고객 지원 부서

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문


문서

Professor Robert K. Prud’homme introduces flash nanoprecipitation (FNP) for nanoparticle fabrication, which is a scalable, rapid mixing process for nanoparticle formulations.

NanoFabTx™ platform accelerates drug development with ready-to-use formulations and microfluidic devices for particle synthesis.

NanoFabTX kits enable precise drug delivery with lipid nanoparticles and liposomes for mRNA and nucleic acids.

관련 콘텐츠


Solène Passemard et al.
Biomacromolecules, 18(9), 2747-2755 (2017-07-26)
The production of hydrogel microspheres (MS) for cell immobilization, maintaining the favorable properties of alginate gels but presenting enhanced performance in terms of in vivo durability and physical properties, is desirable to extend the therapeutic potential of cell transplantation. A
Xu Jia et al.
ACS biomaterials science & engineering, 2(9), 1641-1648 (2016-09-12)
Theranostic nanomedicine has recently emerged as an appealing approach for tumor chemotherapy. Here, for the first time, fluorescent carbon dots (Cdots) were used as cross-linker for tumor theranostic nanoparticles. Novel theranostic nanoparticles of approximately 27 nm with a doxorubicin (DOX)
Redouan Mahou et al.
Materials (Basel, Switzerland), 7(1), 275-286 (2014-01-09)
The progress of medical therapies, which rely on the transplantation of microencapsulated living cells, depends on the quality of the encapsulating material. Such material has to be biocompatible, and the microencapsulation process must be simple and not harm the cells.



국제 무역 품목 번호

SKUGTIN
920436-1KT04065266037487